NEW YORK (GenomeWeb News) – Veridex and Novartis are partnering to "encourage and facilitate" research into circulating tumor cells as potential biomarkers in metastatic prostate cancer, Veridex announced today.

As part of the deal, Veridex is supporting a prospective, single-arm, open-label study on the effect of zoledronic acid — marketed by Novartis as Zometa — on circulating tumors in patients with metastatic castration-resistant prostate cancer, or CRPC.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

University of California, San Diego, researchers have developed a gene drive to control a fruit-destroying fly.

A new study of a β-thalassemia gene therapy appears promising, according to NPR.

In Nature this week: hair color genes, hybridization between 13-year and 17-year cicadas, and more.

Futurism writes that gene doping could be the next generation of cheating in sports.

May
15
Sponsored by
Tecan

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.

Jun
20
Sponsored by
PerkinElmer

In this webinar, Michael Quail of the R&D Sequencing team at the Wellcome Trust Sanger Institute will provide an expert perspective on library prep for next-generation sequencing.

Jun
28
Sponsored by
PerkinElmer

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.